All News

Narrow provider networks are gaining ground among insurers and could impact patient access to urologists. While insurers tout the approach to care as a way to control costs and preserve quality, urologists and others question whether the payment model is all about cost.

Use of targeted magnetic resonance/ultrasound fusion biopsy (“targeted biopsy”) resulted in the diagnosis of significantly more high-risk prostate cancers and significantly fewer low-risk cancers compared with a standardized systematic biopsy technique, reported the authors of a new study from the National Cancer Institute.

In a series of articles, urologist Robert A. Dowling, MD, reviews aspects of the National Quality Forum's “Safe Practices for Better Healthcare” consensus recommendations that are relevant to quality and safety in urologic practice.

In this interview, Patrick H. McKenna, MD, former chairman of the AUA’s Judicial & Ethics Committee, discusses self-referral as well as the AUA expert witness program, conflicts of interest, and live surgical demonstrations.

If further work with irreversible electroporation refines its capacity for discrete tissue ablation deep within the kidney and adjacent to large blood vessels, and especially if larger tumors can be addressed, then this would be a major step forward in the minimally invasive treatment of localized renal cancer.

Percutaneous irreversible electroporation is showing promise as a novel minimally invasive approach for treating small renal tumors, according to the experience of urologists at the University of Texas Southwestern Medical Center, Dallas.

African-American men with very low-risk prostate cancer being followed on active surveillance are at significantly higher risk for disease upgrading on subsequent biopsy compared to Caucasian men, according to analyses of prospectively collected data from the Johns Hopkins Active Surveillance registry.

When choosing a life insurance product, time needs to be spent on the intricacies of how those death benefits pass to the intended heirs, and how your estate is impacted, prior to making the purchase.

Catch up on February’s best-read Urology Times articles, including our coverage of the AUA’s recent statement on NPs/PAs, a malpractice case involving removal of a cancer-free testicle, and a Q&A on diversity in urology.

Urologists attending the 2015 Urology Joint Advocacy Conference will have the opportunity to make their voices heard on Capitol Hill at a pivotal time for physicians.